Salarius Pharmaceuticals Inc.
13F holders, Q3 2024 (September 30)7holders −1
1new positions
2sold out
$1.44avg. 13F price*
At the end of Q3 2024, 7 institutions reported holding Salarius Pharmaceuticals Inc. in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were Tower Research Capital LLC (TRC) ($5K), Citigroup Inc. ($2K) and UBS Group AG ($375).
- Company
- Salarius Pharmaceuticals Inc.
- CUSIP
- 79400X404
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 2 | $54K |
All 13F filers, Q2 2024 → Q3 2024: 1,889 shares bought and 22,751 shares sold, net −20,862 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.3% | 3,189 | $5K |
| Citigroup Inc. | 0.00% | New | 1,610 | $2K |
| UBS Group AG | 0.00% | Add +130.1% | 260 | $375 |
| Osaic Holdings, Inc. | 0.00% | Add +205.7% | 162 | $232 |
| Bank of America Corp. | 0.00% | Add +200.0% | 18 | $26 |
| Morgan Stanley | 0.00% | No change | 7 | $10 |
| BlackRock, Inc. | 0.00% | — | 1 | $1 |
"% of holder's portfolio" is SALARIUS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Salarius Pharmaceuticals Inc. the manager owns.